Omthera Pharmaceuticals, Inc., a Bedminster, New Jersey-based pharmaceutical company focusing on the clinical development of new dyslipidemia therapies, closed a $6.5m Series A financing.
The round, which was led by Sofinnova Partners will be used to advance Omthera’s lead product candidate, Epanova™, an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
The product has shown promising results in lowering triglycerides in earlier clinical trials, as well as an excellent safety and tolerability profile.
The company, which today announced commencement of operations, holds worldwide rights to Epanova.
The Omthera management team includes drug development and commercialization expert Jerry Wisler, president and chief executive officer, and cardiologist and clinical expert Michael Davidson, M.D., chief medical officer.